Showing results (471-480 of 6,286) with videos related to

Sort By:
Pageof 629
Diabetes, Obesity & Metabolism|September 1, 2025
Raised levels of Interleukin-8 and myeloperoxidase in patients with recent onset type 1 diabetesGhadeer Alhamar, Sara Fallucca, Sarah J Richardson, et al.
Diabetes, Obesity & Metabolism|September 5, 2025
The protective role of TIGIT+ B cells in attenuating type 1 diabetes progressionYiman Peng, Jingyue Li, Ying Deng, et al.
Diabetes, Obesity & Metabolism|September 3, 2025
Identification of subtypes of type 2 diabetes in the Chinese population and their distinct complication risk profilesQiu Xiao, Chengjun Zhang, Yanfeng Jiang, et al.
Diabetes, Obesity & Metabolism|September 1, 2025
Integrative proteomic analysis provides novel therapeutic insights for etiological subtypes of diabetesJiahe Wei, Hanzhang Wu, Ningjian Wang, et al.
Diabetes, Obesity & Metabolism|September 2, 2025
Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trialAlina N Saidi, Laura A M Konings, Carmen A W Dietvorst, et al.
Diabetes, Obesity & Metabolism|April 9, 2020
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEYJinnie J Rhee, Meg J Jardine, Glenn M Chertow, et al.
Diabetes, Obesity & Metabolism|May 16, 2020
A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian modelsTito Borner, Evan D Shaulson, Ian C Tinsley, et al.
Diabetes, Obesity & Metabolism|May 20, 2020
Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight lossHusam Ghanim, Manav Batra, Kelly Green, et al.
Diabetes, Obesity & Metabolism|June 19, 2015
Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)J Vora, N Cohen, M Evans, et al.
Diabetes, Obesity & Metabolism|June 5, 2015
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trialJ Rosenstock, A Jelaska, C Zeller, et al.
Pageof 629